Wellspring Blog

As your organization’s researchers innovate, your intellectual property (IP) portfolio exponentially grows over time. However, that does not always mean that the number of staff members in your TTO grows alongside it. As a result, it is necessary to develop new strategies to make your team’s... Read More

Organized workflow management can make or break an office. As soon as a staff member logs into Sophia, they play a role in enabling your team to develop and grow a robust portfolio of technologies and IP. How can you support this process as a system administrator? Read More

In North America, the AUTM Licensing Activity Survey reports annual disclosures have increased 24% over the past 7 years, resulting in cumulative patents under management growing at an exponential rate. Simultaneously, universities and hospitals have not expanded staff systematically to oversee... Read More

  Read More

It’s no secret that university technology commercialization is flourishing. Corporate sponsorship of university research has grown over 50% in the last few years, universities reported almost double the number of start-ups compared to a decade ago, and we have witnessed year-on-year, sustained... Read More

Last week Barcelona was the place to be with both the colossal Mobile World Congress and the much more targeted Breakthrough Innovations (BI) conference. BI was focused on innovative product development with product leaders from a range of industries, including telecom to consumer products to... Read More

I'm delighted to announce today that Wellspring has closed a $5M round of growth capital led by MK Capital. We concluded 2013 with our strongest year to date, posting substantial, profitable growth in each of our major sectors: academic markets, corporate innovation / R&D, and health care.... Read More

Its not often you go to Mars. But I spent the last week there and, while its very very hot from a temperature standpoint, the technology and infrastructure are the more impressive aspects. Read More

Pfizer and the NIH have taken sides on who owns background intellectual property (IP) rights to the blockbuster arthritis drug Xeljanz. Its undisputed that Pfizer invested over $1B in the drug, and its undisputed that Pfizer and NIH had an joint R&D contract, called a CRADA, in place during the... Read More

R&D has not typically reported on the process they use to generate new innovative ideas, but more often the results. Prior to the advent of the Open Innovation as a business activity R&D had no reason to report on the amount of external collaborations or external partner’s contributions to research... Read More